단순포진바이러스(HSV) 치료 시장 보고서, 규모, 점유율, 동향, 예측 : 유형별, 약제 유형별, 투여 경로별, 유통 채널별, 지역별(2025-2033년)

The global herpes simplex virus treatment market size was valued at USD 2.7 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 4.0 Billion by 2033, exhibiting a CAGR of 4.51% during 2025-2033. North America currently dominates the market. The growing awareness among individuals about various medications of HSV, increasing healthcare expenditure, and wide availability of HSV medications through online and offline pharmacy stores represent some of the key factors driving the market.

Herpes simplex virus (HSV) refers to a contagious viral infection that is spread through saliva, semen, and vaginal secretion and causes blisters and ulcers. It produces herpes simplex virus-1 (HSV-1) infection and herpes simplex virus-2 (HSV-2) infection among individuals. It also causes fever, body aches, swollen lymph nodes, headache, tingling, itching, or burning sensation around the mouth of an individual before the appearance of sores. It usually occurs among people having a sexual partner with HSV or who are immunocompromised. HSV can be cured by consuming some antiviral medications, such as acyclovir, famciclovir, and valacyclovir. It can also be treated through some home remedies, such as a warm or cold compress, aloe vera, a paste of baking soda or cornstarch and water, and a mixture of crushed garlic. HSV treatment can aid in lowering the chance of transmitting the virus and reducing the frequency or severity of outbreaks.

Herpes Simplex Virus Treatment Market Trends:

At present, the rising prevalence of sexually transmitted infections (STIs) among the masses around the world represents one of the key factors supporting the growth of the market. In addition, the increasing demand for HSV treatments due to concerns about sexual health among individuals worldwide is bolstering the growth of the market. Besides this, the growing demand for HSV treatments due to the increasing awareness among individuals about the risks and complications of HSV infection across the globe is positively influencing the market. Moreover, the rising demand for new HSV treatment options with reduced side effects and enhanced effectiveness is propelling the growth of the market. Apart from this, the increasing healthcare expenditure, along with the inflating income level of individuals, is offering lucrative growth opportunities to industry investors. Additionally, the wide availability of HSV medications through online and offline pharmacy stores across the globe is impelling the growth of the market. Besides this, the increasing demand for HSV treatment options to prevent severe complications, such as encephalitis (brain infection) or keratitis (eye infection) among individuals, is contributing to the growth of the market. Furthermore, the rising innovations in HSV treatment options and various drug approvals are strengthening the growth of the market.

Key Market Segmentation:

Type Insights:

• Herpes Simples Virus-1 Infection
• Herpes Simplex Virus-2 Infection
• Others

Drug Type Insights:

• Acyclovir
• Valacyclovir
• Famciclovir
• Others

Route of Administration Insights:

• Oral
• Injectable
• Topical

Distribution Channel Insights:

• Hospital Pharmacy
• Drug Stores
• Retail Stores
• Online Pharmacy

Regional Insights:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for herpes simplex virus treatment. Some of the factors driving the North America herpes simplex virus treatment market included the growing prevalence of HSV infection among individuals, increasing number of clinical trials for its treatment, rising awareness about various medications of HSV, etc.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global herpes simplex virus treatment market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Agenus Inc., Apotex Inc., Avet Pharmaceuticals Inc., Carlsbad Tech, EPI Health LLC, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

• 1.How big is the herpes simplex virus treatment market?
• 2.What is the future outlook of the herpes simplex virus treatment market?
• 3.What are the key factors driving the herpes simplex virus treatment market?
• 4.Which region accounts for the largest herpes simplex virus treatment market share?
• 5.Which are the leading companies in the global herpes simplex virus treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Herpes Simplex Virus Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Herpes Simples Virus-1 Infection
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Herpes Simplex Virus-2 Infection
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Drug Type

• 7.1 Acyclovir
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Valacyclovir
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Famciclovir
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Oral
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Injectable
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Topical
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacy
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Drug Stores
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Retail Stores
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Online Pharmacy
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Agenus Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Apotex Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 SWOT Analysis
  • 15.3.3 Avet Pharmaceuticals Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Carlsbad Tech
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 EPI Health LLC
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 F. Hoffmann-La Roche Ltd
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Fresenius SE & Co. KGaA
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 GlaxoSmithKline plc
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Glenmark Pharmaceuticals Limited
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Merck & Co. Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Novartis AG
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Sanofi S.A.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Teva Pharmaceutical Industries Ltd.
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials
    • 15.3.13.4 SWOT Analysis
  • 15.3.14 Viatris Inc.
    • 15.3.14.1 Company Overview
    • 15.3.14.2 Product Portfolio
    • 15.3.14.3 Financials